Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 2014. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and does not contain financial performance data.
Material Changes
The filing details the company's issued share capital as of January 31, 2014:
- Total Issued Ordinary Shares: 5,344,579,088 (25p each)
- Treasury Shares: 487,433,663
- Total Voting Rights: 4,857,145,425
No comparative data for prior periods is included in this specific filing to determine material changes in share count.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,857,145,425) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (487,433,663) to calculate the net outstanding share count.
- Note that this filing does not contain financial results; refer to Form 20-F or quarterly reports for performance metrics.